Pirfenidone Dose Escalation Scheme for Adverse Event Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pirfenidone therapy is limited by adverse events such as nausea, gastrointestinal upset, and dizziness, which are exacerbated at higher doses, necessitating dose reduction or discontinuation, and there is a need for a more optimized dose escalation scheme to minimize these side effects.
Innovation Solution
An improved dose escalation scheme for pirfenidone administration that reaches the full maximum dosage of 2,403 mg/day by Day 15, allowing for gradual tolerance development and reducing adverse events, involving a three-step dosage regimen with initial, intermediate, and final daily doses of pirfenidone ranging from 801 mg to 2,403 mg over specific time periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pirfenidone is administered at higher doses to achieve therapeutic benefits, then the effectiveness of treating fibrosis conditions is improved, but the incidence of adverse events such as gastrointestinal upset, nausea, fatigue, and somnolence increases
Solution Approach 1:
The patent implements a preliminary action by initiating dose escalation before the full therapeutic dose is reached. The method starts with a low initial dose (e.g., 200 mg three times daily) and progressively increases to the target dose (e.g., 2403 mg daily) over an extended period (at least 15 days). This preliminary dose escalation allows patients to develop tolerance to the drug before receiving full therapeutic doses, thereby reducing the incidence of adverse events while maintaining treatment effectiveness.
2Object-affected harmful factors
If the dose of pirfenidone is increased to reduce adverse events through tolerance development, then the incidence of side effects decreases, but the time required to reach full therapeutic dosage is extended
Solution Approach 1:
The patent applies dynamics by implementing a flexible, adaptive dose escalation schedule rather than a fixed dosing regimen. The method allows for progressive dose increases based on patient tolerance development, where the escalation rate can be adjusted to match individual patient responses. This dynamic approach optimizes the balance between reaching full therapeutic dosage and minimizing adverse events, rather than using a static dosing schedule.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying the dosage parameter over time. The method transitions from low initial doses to higher therapeutic doses through controlled increments, changing the dosage parameter in a structured manner that allows tolerance development. This parameter change strategy enables the system to achieve both reduced adverse events and eventual full therapeutic effect.
3Productivity
If a rapid dose escalation schedule is used to reach maximum dosage quickly, then the treatment duration is shortened, but the incidence of adverse events increases significantly
Solution Approach 1:
The patent counters rapid dose escalation by implementing preliminary action through extended dose titration. Instead of quickly reaching maximum dosage, the method requires a minimum of 15 days to escalate from initial to full therapeutic doses. This preliminary extended escalation period allows physiological adaptation and tolerance development, significantly reducing adverse events while maintaining acceptable treatment efficiency.
Data Source
Figure 1~3
Figure 4
Figure 5
AI summary
The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.